Cardiovascular disease in rheumatoid arthritis
- 1 May 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 18 (3) , 289-297
Abstract
Individuals with rheumatoid arthritis are at increased risk for morbidity and mortality from cardiovascular disease (CVD). The purpose of this review is to discuss recent advances in our understanding of the pathogenesis, prevalence, treatment, and prevention of accelerated atherosclerotic disease in rheumatoid arthritis. Recent reports have highlighted the increased risk for silent myocardial infarction and sudden death in rheumatoid arthritis, and the potential roles of traditional and nontraditional risk factors for CVD, including abnormal revascularization of damaged peripheral blood vessels and genetic polymorphisms. Several studies have also added important information on the possible role of anti-tumor necrosis factor-alpha therapy, other disease modifying antirheumatic drugs, and nonsteroidal anti-inflammatory drugs in decreasing CVD risk. The pathogenic mechanisms involved in accelerated cardiovascular complications in rheumatoid arthritis appear to be complex and multifactorial. Both traditional and nontraditional risk factors potentially contribute to the increased cardiovascular risk. Good control of the inflammation, immunologic disturbances, and metabolic changes seen in rheumatoid arthritis are crucial in the prevention of this potentially lethal complication. There is a need for heightened awareness of the increased risk for silent ischemia, early myocardial infarction, and sudden death. Further exploration of the mechanisms of vascular repair and their potential role in premature atherosclerosis is needed.Keywords
This publication has 83 references indexed in Scilit:
- Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritisArthritis & Rheumatism, 2005
- Arterial Stiffness in Chronic Inflammatory DiseasesHypertension, 2005
- Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS)Circulation, 2005
- Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005
- Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitorsKidney International, 2005
- Cardiovascular death in rheumatoid arthritis: A population‐based studyArthritis & Rheumatism, 2005
- Plasminogen Activation/Plasmin in Rheumatoid ArthritisThe American Journal of Pathology, 2005
- Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: Possible role in synovial neovascularizationArthritis & Rheumatism, 2004
- Cell adhesion molecules in rheumatoid arthritisCurrent Opinion in Rheumatology, 1995
- Serum lipids and lipoprotein concentrations in women with rheumatoid arthritisClinical Rheumatology, 1983